Alimera Sciences Inc (ALIM)

[mick]

wow wowzer read peter/\Alimera Sciences (ALIM) Announces Regulatory Approval for ILUVIEN in Benelux Countries for Treatment of Non-Infectious Posterior Uveitis

https://www.streetinsider.com/Corporate+News/Alimera+Sciences+%28ALIM%29+Announces+Regulatory+Approval+for+ILUVIEN+in+Benelux+Countries+for+Treatment+of+Non-Infectious+Posterior+Uveitis/16202783.html


Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that the governmental agencies that oversee the availability of medical products in Belgium, The Netherlands and Luxembourg, collectively known as the Benelux countries, have each granted marketing authorization for ILUVIEN® for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.

The complete Benelux approval was achieved when The Netherlands’ Medicines Evaluation Board informed Alimera of their approval on November 6, 2019. The approval by Belgium’s Federal Agency for Medicines and Health Products was received in May of 2019, and Luxembourg’s Heads of Medicines Agencies provided its confirmation of regulatory approval in late October. Alimera announced in September that it was expanding its relationship with French distribution partner, Horus Pharmaceuticals, who will help the Company achieve reimbursement in all three countries, after which it will oversee distribution throughout Benelux for the new indication.

“We are pleased to now have the approvals for this new indication for ILUVIEN across Benelux so that our partner, Horus Pharmaceuticals, can now pursue reimbursement in each of these markets for both diabetic macular edema and posterior segment non-infectious uveitis,” said Rick Eiswirth, president and CEO of Alimera.

“Following a strong launch in France for diabetic macular edema,
we are excited to see what Horus can do with ILUVIEN in these countries, providing us with additional markets in Europe where we believe ILUVIEN can help physicians control the recurrence of disease in patients who have either of these conditions.”

See http://www.ILUVIEN.com for important safety information.